Morgan Stanley In8 Bio, Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.77 - $2.89 $908 - $1,482	513 Added 51.3%	1,513 $3,000
Q2 2022 Oct 27, 2022	SELL	$2.02 - $4.68 $3,880 - $8,990	-1,921 Reduced 65.77%	1,000 $2,000
Q2 2022 Aug 15, 2022	SELL	$2.02 - $4.68 $3,880 - $8,990	-1,921 Reduced 65.77%	1,000 $2,000
Q1 2022 Oct 27, 2022	BUY	$2.76 - $4.6 $5,301 - $8,836	1,921 Added 192.1%	2,921 $10,000
Q1 2022 May 13, 2022	BUY	$2.76 - $4.6 $2,740 - $4,567	993 Added 51.5%	2,921 $10,000
Q4 2021 Feb 14, 2022	BUY	$4.39 - $8.55 $7,585 - $14,774	1,728 Added 864.0%	1,928 $8,000
Q3 2021 Nov 15, 2021	BUY	$6.71 - $10.0 $1,342 - $2,000	200 New	200 $1,000

7.62M

Ticker INAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,502,200
Market Cap $6.13M
Description
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.